Denmark’s Novo Nordisk has in-licenced a potential non-alcoholic steatohepatitis (NASH) candidate from Japanese chemical company, UBE Industries.
The exclusive worldwide license grants Novo Nordisk access to UBE’s preclinical asset UD-014, a selective Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) inhibitor small molecule.
In preclinical studies, the asset has shown promising efficacy for its anti-inflammatory mechanism of action and antioxidative effect on endothelial cells and can potentially be used for the treatment of NASH.
UBE will receive an upfront payment as well as development and sales milestones plus tiered royalties on the annual net sales. Novo Nordisk will be responsible for the further development, manufacturing and commercialisation of UD-014.